Lee Golden
Vermögen: 6 Mio $ am 31.05.2026
Vermögen: 6 Mio $ am 31.05.2026
Dr. Lee S.
Golden, MD, is an Independent Director at Cadrenal Therapeutics, Inc. and a Chief Medical Officer & Executive Vice President at PTC Therapeutics, Inc. He is on the Board of Directors at Cadrenal Therapeutics, Inc. Dr. Golden was previously employed as a Chief Medical Officer by Espero Pharmaceuticals, Inc., a Chief Medical Officer by Gemphire Therapeutics, Inc., a Head-Pulmonary by Mesoblast Ltd., a Head-Cardiovascular & Blood Disorders by Eisai, Inc., a Senior Director-US Medical by Actelion Pharmaceuticals US, Inc., and a Medical Director by Pfizer Inc. He also served on the board at Coagulation Sciences LLC.
He received his undergraduate degree from the University of Michigan and a doctorate degree from New York University School of Medicine.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 10.04.2026 | 79 964 ( 0,1 % ) | 6 Mio $ | 31.05.2026 | |
| 02.12.2025 | 1 667 ( 0,06 % ) | 8 268 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| PTC THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2022 |
| CADRENAL THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 24.11.2025 |
| Unternehmen | Position | Ende |
|---|---|---|
Espero Pharmaceuticals, Inc.
Espero Pharmaceuticals, Inc. Medical DistributorsDistribution Services Manufactures and supplies drugs related to cardiovascular | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2020 |
| METAVIA INC. | Technik-/Wissenschafts-/F&E-Leiter | 18.09.2018 |
| MESOBLAST LIMITED | Corporate Officer/Principal | 01.10.2016 |
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Manufacturers pharmaceutical products | Corporate Officer/Principal | 01.07.2011 |
Actelion Pharmaceuticals US, Inc.
Actelion Pharmaceuticals US, Inc. Pharmaceuticals: MajorHealth Technology Manufactures, distributes and markets drugs | Corporate Officer/Principal | 01.03.2008 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 11 |
|---|---|
Pfizer Inc.
Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
PTC Therapeutics, Inc.
PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Manufacturers pharmaceutical products | Health Technology |
University of Michigan
University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mesoblast Ltd.
Mesoblast Ltd. BiotechnologyHealth Technology Engages in the development and commercialization of biological and adult stem cells products | Health Technology |
Actelion Pharmaceuticals US, Inc.
Actelion Pharmaceuticals US, Inc. Pharmaceuticals: MajorHealth Technology Manufactures, distributes and markets drugs | Health Technology |
New York University School of Medicine
New York University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Coagulation Sciences LLC
Coagulation Sciences LLC Medical/Nursing ServicesHealth Services Provides blood-testing solutions | Health Services |
Gemphire Therapeutics, Inc.
Gemphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapies for the treatment of Dyslipidemia | Health Technology |
Espero Pharmaceuticals, Inc.
Espero Pharmaceuticals, Inc. Medical DistributorsDistribution Services Manufactures and supplies drugs related to cardiovascular | Distribution Services |
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel therapy with orphan drug indication | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen